Skip to Main Content

Paper Details

Defining the therapeutic selective dependencies for distinct subtypes of PI3K pathway-altered prostate cancers.
Nat Commun
15
2021
AKT, IGF1R, Insulin Like Growth Factor 1 Receptor, PI3K, PIK3CA, PIK3CA-, PIK3CB, PTEN, PTEN-deficient tumors, p110, prostate cancers, wild-type PTEN
Author NameAffiliation
Zhigang ZhangMemorial Sloan Kettering Cancer Center
Zhigang ZhangMemorial Sloan Kettering Cancer Center
Elisa de StanchinaMemorial Sloan Kettering Cancer Center
Charles L SawyersMemorial Sloan Kettering Cancer Center
Charles L SawyersHoward Hughes Medical Institute, Memorial Sloan Kettering Cancer Center
Yu ChenMemorial Sloan Kettering Cancer Center
Yu ChenMemorial Sloan Kettering Cancer Center
  • 1 - 7

Datasets

Release 1.2